Global Next Generation Antibody Therapeutics 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI01242718

Publication Date:

January 4, 2024

Pages:

107

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Next Generation Antibody Therapeutics market size was valued at US$ 9392.2 million in 2023. With growing demand in downstream market, the Next Generation Antibody Therapeutics is forecast to a readjusted size of US$ 38470 million by 2030 with a CAGR of 22.3% during review period.
The research report highlights the growth potential of the global Next Generation Antibody Therapeutics market. Next Generation Antibody Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Next Generation Antibody Therapeutics. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Next Generation Antibody Therapeutics market.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.
Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.
Key Features:
The report on Next Generation Antibody Therapeutics market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Next Generation Antibody Therapeutics market. It may include historical data, market segmentation by Type (e.g., Antibody Drug Conjugate (ADC), Bispecific Antibody (BsAb)), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Next Generation Antibody Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Next Generation Antibody Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Next Generation Antibody Therapeutics industry. This include advancements in Next Generation Antibody Therapeutics technology, Next Generation Antibody Therapeutics new entrants, Next Generation Antibody Therapeutics new investment, and other innovations that are shaping the future of Next Generation Antibody Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Next Generation Antibody Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Next Generation Antibody Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Next Generation Antibody Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Next Generation Antibody Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Next Generation Antibody Therapeutics market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Next Generation Antibody Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Next Generation Antibody Therapeutics market.
麻豆原创 Segmentation:
Next Generation Antibody Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)
Segmentation by application
Cancer
Haemophilia
Other Non-Cancer Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Next Generation Antibody Therapeutics 麻豆原创 Size 2019-2030
2.1.2 Next Generation Antibody Therapeutics 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Next Generation Antibody Therapeutics Segment by Type
2.2.1 Antibody Drug Conjugate (ADC)
2.2.2 Bispecific Antibody (BsAb)
2.3 Next Generation Antibody Therapeutics 麻豆原创 Size by Type
2.3.1 Next Generation Antibody Therapeutics 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Next Generation Antibody Therapeutics 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Next Generation Antibody Therapeutics Segment by Application
2.4.1 Cancer
2.4.2 Haemophilia
2.4.3 Other Non-Cancer Diseases
2.5 Next Generation Antibody Therapeutics 麻豆原创 Size by Application
2.5.1 Next Generation Antibody Therapeutics 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Next Generation Antibody Therapeutics 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Next Generation Antibody Therapeutics 麻豆原创 Size by Player
3.1 Next Generation Antibody Therapeutics 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Next Generation Antibody Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Next Generation Antibody Therapeutics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Next Generation Antibody Therapeutics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Next Generation Antibody Therapeutics by Regions
4.1 Next Generation Antibody Therapeutics 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Next Generation Antibody Therapeutics 麻豆原创 Size Growth (2019-2024)
4.3 APAC Next Generation Antibody Therapeutics 麻豆原创 Size Growth (2019-2024)
4.4 Europe Next Generation Antibody Therapeutics 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Next Generation Antibody Therapeutics 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Next Generation Antibody Therapeutics 麻豆原创 Size by Country (2019-2024)
5.2 Americas Next Generation Antibody Therapeutics 麻豆原创 Size by Type (2019-2024)
5.3 Americas Next Generation Antibody Therapeutics 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Next Generation Antibody Therapeutics 麻豆原创 Size by Region (2019-2024)
6.2 APAC Next Generation Antibody Therapeutics 麻豆原创 Size by Type (2019-2024)
6.3 APAC Next Generation Antibody Therapeutics 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Next Generation Antibody Therapeutics by Country (2019-2024)
7.2 Europe Next Generation Antibody Therapeutics 麻豆原创 Size by Type (2019-2024)
7.3 Europe Next Generation Antibody Therapeutics 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Next Generation Antibody Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Next Generation Antibody Therapeutics 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Next Generation Antibody Therapeutics 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.1 Global Next Generation Antibody Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Next Generation Antibody Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Next Generation Antibody Therapeutics Forecast
10.1.3 APAC Next Generation Antibody Therapeutics Forecast
10.1.4 Europe Next Generation Antibody Therapeutics Forecast
10.1.5 Middle East & Africa Next Generation Antibody Therapeutics Forecast
10.2 Americas Next Generation Antibody Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.2.2 Canada Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.2.3 Mexico Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.2.4 Brazil Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.3 APAC Next Generation Antibody Therapeutics Forecast by Region (2025-2030)
10.3.1 China Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.3.2 Japan Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.3.3 Korea Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.3.4 Southeast Asia Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.3.5 India Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.3.6 Australia Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.4 Europe Next Generation Antibody Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.4.2 France Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.4.3 UK Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.4.4 Italy Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.4.5 Russia Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.5 Middle East & Africa Next Generation Antibody Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.5.2 South Africa Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.5.3 Israel Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.5.4 Turkey Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.5.5 GCC Countries Next Generation Antibody Therapeutics 麻豆原创 Forecast
10.6 Global Next Generation Antibody Therapeutics Forecast by Type (2025-2030)
10.7 Global Next Generation Antibody Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Next Generation Antibody Therapeutics Product Offered
11.1.3 Roche Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Next Generation Antibody Therapeutics Product Offered
11.2.3 Amgen Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Next Generation Antibody Therapeutics Product Offered
11.3.3 Pfizer Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Takeda
11.4.1 Takeda Company Information
11.4.2 Takeda Next Generation Antibody Therapeutics Product Offered
11.4.3 Takeda Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Takeda Main Business Overview
11.4.5 Takeda Latest Developments
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Information
11.5.2 Daiichi Sankyo Next Generation Antibody Therapeutics Product Offered
11.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Daiichi Sankyo Main Business Overview
11.5.5 Daiichi Sankyo Latest Developments
11.6 Seagen
11.6.1 Seagen Company Information
11.6.2 Seagen Next Generation Antibody Therapeutics Product Offered
11.6.3 Seagen Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Seagen Main Business Overview
11.6.5 Seagen Latest Developments
11.7 Astellas
11.7.1 Astellas Company Information
11.7.2 Astellas Next Generation Antibody Therapeutics Product Offered
11.7.3 Astellas Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Astellas Main Business Overview
11.7.5 Astellas Latest Developments
11.8 Immunomedics
11.8.1 Immunomedics Company Information
11.8.2 Immunomedics Next Generation Antibody Therapeutics Product Offered
11.8.3 Immunomedics Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Immunomedics Main Business Overview
11.8.5 Immunomedics Latest Developments
11.9 GSK
11.9.1 GSK Company Information
11.9.2 GSK Next Generation Antibody Therapeutics Product Offered
11.9.3 GSK Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 GSK Main Business Overview
11.9.5 GSK Latest Developments
11.10 Immunocore
11.10.1 Immunocore Company Information
11.10.2 Immunocore Next Generation Antibody Therapeutics Product Offered
11.10.3 Immunocore Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Immunocore Main Business Overview
11.10.5 Immunocore Latest Developments
11.11 ADC Therapeutics
11.11.1 ADC Therapeutics Company Information
11.11.2 ADC Therapeutics Next Generation Antibody Therapeutics Product Offered
11.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 ADC Therapeutics Main Business Overview
11.11.5 ADC Therapeutics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.